AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$KMDA

Tsur David sold $187K of KMDA

Tsur David sold 22,827 shares of KAMADA LTD (KMDA) at $8.18 ($0.19M total) on 2026-09-14.

Original reporting
SEC EDGAR · Tsur David
Published Sep 17, 2026, 3:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMDA
Bearish
medium confidence
Mentioned
$KMDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMDABearishLow
01

Why it matters

The sale reduces insider ownership, which can be interpreted as a slight bearish signal.

02

Market read

Provides fresh insider transaction data for traders monitoring KMDA.

03

What to watch

Potential upcoming corporate events or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post-market filing

Background

Form 4 filing by a director discloses a recent open-market sale of company stock.

Company-level read

Ticker impact

$KMDABearishMedium confidence
Context

Director Tsur David sold 22,827 shares for $186,724, reducing his stake to 407,929 shares.

Expected impact

Possible modest dip in near-term trading as market digests insider sell.

Evidence & confidence

Sale size is modest relative to holdings; typical insider sell effect is limited but could influence sentiment.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No significant regional effect.

Global

Limited to investors tracking KMDA.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate negative outlook.

Key entities

  • Company
    Kamada Ltd

    Biotech company listed on Nasdaq under KMDA.

  • Individual
    Tsur David

    Director of Kamada Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMDA insider trading history →

Related articles

AUG 19
$KMDAMed

Kamada (KMDA) Q2 2026 Earnings Call Transcript

Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.

yahoo.com2 min
AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
AUG 12
$KMDAMed

KAMADA LTD (KMDA): Financial results for H1 2026

KAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year

SEC EDGAR 6-K2 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min